- Home
- GWRS vs GALT Comparison
GWRS vs GALT Comparison
Compare GWRS & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GWRS | GALT |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.3M | 199.2M |
| IPO Year | 2008 | 2008 |
Fundamental Metrics
Financial Performance| Metric | GWRS | GALT |
|---|---|---|
| Price | $7.12 | $2.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.20 | $8.50 |
| AVG Volume (30 Days) | 79.2K | ★ 277.6K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,914,000.00 | N/A |
| Revenue This Year | $15.29 | N/A |
| Revenue Next Year | $8.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.51 | N/A |
| 52 Week Low | $6.55 | $1.22 |
| 52 Week High | $11.17 | $7.13 |
Technical Indicators
Market Signals| Indicator | GWRS | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 56.58 |
| Support Level | $7.19 | $2.10 |
| Resistance Level | $7.82 | $2.60 |
| Average True Range (ATR) | 0.22 | 0.18 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 98.77 | 77.70 |
Price Performance
Historical ComparisonAbout GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix and Tucson, Arizona. It operates within the State of Arizona. Operating revenue of the company is derived from regulated water, wastewater, and recycled water service provided to customers based upon tariff rates.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.